Company / Revenue
ADMA Biologics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$510.2M
FY2025
5-year range
$80.9M / $510.2M
FY2021-FY2025
Trend
+19.6%
vs FY2024
Sector context
#64 of 155
Health Care
What the data says
At $510M, ADMA Biologics, Inc.'s revenue ranks #64 of 155 in the Health Care sector. Revenue has increased for 3 consecutive years, from $81M in FY2022 to $510M in FY2025.
Based on SEC 10-K filings.
$510M in FY2025 with a 5-year CAGR of +64.6%.
Improved from $258M to $510M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +84.7%
- 5-Year CAGR
- +64.6%
- 10-Year CAGR
- -
Sector benchmark
#64 of 155 in Health CareTop 41% of 155This company $510.2M Sector average $4.5B
▼
-88.6% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s revenue has grown for 3 consecutive years.
- 5-year CAGR of +64.6%, indicating consistent growth.
- In FY2025, revenue increased 19.6% year-over-year.
- Ranks #64 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $510.2M | +19.6% |
| FY2024 | $426.5M | +65.2% |
| FY2023 | $258.2M | +219.0% |
| FY2022 | $80.9M | -0.0% |
| FY2021 | $80.9M | +91.7% |
| FY2020 | $42.2M | +43.9% |
| FY2019 | $29.3M | +72.8% |
| FY2018 | $17.0M | +59.3% |
| FY2017 | $10.7M | +0.0% |
| FY2016 | $10.7M | +80.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026